aTyr Pharma, Inc.
NCM: ATYRLive Quote
📈 ZcoreAI Score
Our AI model analyzes aTyr Pharma, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ATYR Z-Score →About aTyr Pharma, Inc.
Healthcare
Biotechnology
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
📊 Fundamental Analysis
aTyr Pharma, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -108.1%, which indicates that capital utilization is currently under pressure.
At a current price of $0.83, ATYR currently trades near the bottom of its 52-week range (3%), indicating potential value or weakness (Range: $0.64 - $7.29).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$81.62M
Trailing P/E
--
Forward P/E
-2.07
Beta (5Y)
0.65
52W High
$7.29
52W Low
$0.64
Avg Volume
1.66M
Day High
Day Low